What is the recommended diagnostic and therapeutic management for interstitial lung disease?

Management of Interstitial Lung Disease

For systemic autoimmune rheumatic disease-associated ILD (SARD-ILD), mycophenolate is the preferred first-line therapy across all disease subtypes, while for idiopathic pulmonary fibrosis (IPF), antifibrotic therapy with nintedanib or pirfenidone should be initiated immediately upon diagnosis. 1, 2

Diagnostic Approach

Initial Evaluation

• High-resolution computed tomography (HRCT) of the chest is essential, with approximately 91% sensitivity and 71% specificity for diagnosing ILD subtypes such as IPF 2
• Identify the underlying etiology: Distinguish between idiopathic forms (IPF accounts for ~33% of ILD cases), connective tissue disease-associated (25% of cases), hypersensitivity pneumonitis (15%), and other causes 2
• Assess disease severity and progression risk using forced vital capacity (FVC) and diffusion capacity for carbon monoxide (DLCO) 1, 2

Key Diagnostic Considerations

• A 5% decline in FVC over 12 months is associated with approximately 2-fold increased mortality and defines progressive disease 2
• Multidisciplinary discussion is critical before invasive procedures, particularly when imaging findings are indeterminate 3
• Bronchoscopy with lung cryobiopsy has gained importance for histological diagnosis when CT findings are inconclusive 3

Treatment Strategy by ILD Subtype

Systemic Autoimmune Rheumatic Disease-Associated ILD (SARD-ILD)

First-Line Therapy

Mycophenolate is conditionally recommended as the preferred first-line agent across all SARD-ILD subtypes based on favorable efficacy and safety profile 1

Disease-specific hierarchies:

• Systemic Sclerosis (SSc-ILD): Mycophenolate > Tocilizumab > Rituximab > Cyclophosphamide; nintedanib is also a first-line option 1
• Rheumatoid Arthritis (RA-ILD): Mycophenolate > Azathioprine > Rituximab > Cyclophosphamide 1
• Idiopathic Inflammatory Myopathies (IIM-ILD): Mycophenolate > Azathioprine > Rituximab; JAK inhibitors and calcineurin inhibitors are also first-line options 1
• Sjögren Disease (SjD-ILD): Mycophenolate > Azathioprine > Rituximab > Cyclophosphamide 1
• Mixed Connective Tissue Disease (MCTD-ILD): Mycophenolate > Azathioprine > Rituximab; tocilizumab is also a first-line option 1

Glucocorticoid Use

• For SSc-ILD, strongly recommend AGAINST glucocorticoids as first-line therapy due to increased risk of scleroderma renal crisis, particularly at doses >15 mg/day prednisone equivalent 1
• For other SARD-ILD subtypes, glucocorticoids are conditionally recommended as first-line therapy, but should be short-term (≤3 months) 1

Agents to AVOID as First-Line

• Conditionally recommend AGAINST: Leflunomide, methotrexate, TNF inhibitors, abatacept, and pirfenidone 1
• Do NOT use upfront combination of antifibrotics (nintedanib/pirfenidone) with mycophenolate 1

Progressive SARD-ILD (Despite First-Line Therapy)

When disease progresses on initial therapy:

• Switch to or add: Mycophenolate, rituximab, cyclophosphamide, or nintedanib 1
• For SSc-ILD progression: Strongly recommend AGAINST long-term glucocorticoids 1
• For IIM-ILD progression: Consider calcineurin inhibitors, JAK inhibitors, or IVIG 1
• Decision on nintedanib versus immunosuppression depends on pace of progression, extent of fibrotic disease, and presence of usual interstitial pneumonia pattern on CT 1

Rapidly Progressive ILD (RP-ILD)

This represents a medical emergency requiring aggressive upfront therapy:

• Pulse intravenous methylprednisolone is conditionally recommended as first-line treatment 1
• Upfront combination therapy is preferred over monotherapy: Triple therapy (glucocorticoids + 2 immunosuppressants) for confirmed/suspected anti-MDA-5 antibody; double or triple therapy for others 1
• First-line immunosuppressive options: Rituximab, cyclophosphamide, IVIG, mycophenolate, calcineurin inhibitors, JAK inhibitors 1
• Early referral for lung transplantation is conditionally recommended over waiting for progression on medical management 1

Idiopathic Pulmonary Fibrosis (IPF)

Antifibrotic therapy with nintedanib or pirfenidone should be started as soon as possible after diagnosis 2, 3

• Both agents slow annual FVC decline by approximately 44-57% compared to placebo 2
• Treatment should be long-term; switching to the alternative antifibrotic may be considered for intolerance or significant progression 3
• Combination of both antifibrotics is NOT recommended 3

Hypersensitivity Pneumonitis and Other ILDs

• Antigen avoidance is paramount when a causative exposure is identified 4
• Immunosuppressive therapy may be considered for inflammatory forms 4
• Antifibrotic therapy may be appropriate for progressive fibrosing phenotypes 4

Non-Pharmacologic Management

Essential Supportive Care Measures

• Oxygen therapy reduces symptoms and improves quality of life in patients who desaturate below 88% on 6-minute walk test 2
• Structured exercise therapy/pulmonary rehabilitation reduces symptoms and improves 6-minute walk distance 2, 4
• Treat comorbidities aggressively: Gastroesophageal reflux, pulmonary hypertension (present in up to 85% of end-stage fibrotic ILD), cardiovascular disease 2, 5, 6

Pulmonary Hypertension in ILD

• Up to 85% of individuals with end-stage fibrotic ILD develop pulmonary hypertension 2
• Inhaled treprostinil improves walking distance and respiratory symptoms in ILD-associated PH 2
• Diagnostic workup is complex; right heart catheterization may be needed to distinguish pre-capillary from post-capillary PH 6

Lung Transplantation

Lung transplant should be considered early for patients with advanced ILD:

• Median survival after lung transplant is 5.2-6.7 years compared to <2 years for advanced ILD without transplant 2
• For SSc-ILD with progression despite therapy, conditionally recommend referral for stem cell and/or lung transplantation 1
• For RP-ILD, early referral is preferred over waiting for progression on medical management 1

Monitoring and Prognostic Assessment

• Serial PFTs are essential: A 5% FVC decline over 12 months indicates progression and warrants treatment escalation 2
• HRCT monitoring helps assess extent of fibrosis and disease progression 1
• 6-minute walk test provides functional assessment and identifies oxygen desaturation 2, 4

Critical Pitfalls to Avoid

• Never use glucocorticoids as first-line therapy in SSc-ILD due to renal crisis risk 1
• Do not delay antifibrotic therapy in IPF; start immediately upon diagnosis 2, 3
• Avoid methotrexate and leflunomide as first-line agents in SARD-ILD 1
• Do not combine nintedanib and pirfenidone 3
• Do not delay lung transplant referral in progressive disease; early referral improves outcomes 1, 2

Prognosis

• SARD-ILD has better survival than IPF: Mean survival 56 months versus 33.6 months 7
• Antisynthetase syndrome and dermatomyositis show functional improvement with treatment (FVC increases of ~14% and 13% respectively) 7
• IPF demonstrates progressive decline (FVC decline of ~7.7%) despite antifibrotic therapy 7
• Age and male sex are adverse prognostic factors across all ILD subtypes 7